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The design, synthesis, and X-ray structural analysis of hybrid 
HIV-1 protease inhibitors (PIs) containing bis-tetrahydrofuran 
(bis-THF) in a pseudo-C2-symmetric dipeptide isostere are 
described. A series of PIs were synthesized by incorporating bis-
THF of darunavir on either side of the Phe-Phe isostere of 
lopinavir in combination with hydrophobic amino acids on the 
opposite P2/P2 position. Structure–activity relationship studies 
indicated that the bis-THF moiety can be attached at either the P2 
or P2 position without significantly affecting potency. However, 
the group on the opposite P2/P2 position had a dramatic effect on 
potency depending on the size and shape of the side chain. 
Cocrystal structures of inhibitors with wild-type HIV-1 protease 
revealed that the bis-THF moiety retained similar interactions as 
observed in the darunavir-protease complex regardless of position 
on the Phe-Phe isostere. Analyses of cocrystal structures and 
molecular dynamics simulations provide insights for optimizing 
HIV-1 PIs containing bis-THF in non-sulfonamide dipeptide 
isosteres.
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Combinations of drugs targeting HIV-1 enzymes essential for viral 
replication have been highly effective in reducing viral load in 
infected individuals and significantly increasing their life 
expectancy.1 HIV-1 protease inhibitors (PIs) have played an 
important role as a highly potent component of combination 
antiretroviral therapy (cART) for people living with HIV-1. There 
are nine HIV-1 PIs approved by the US FDA; however, clinical use 
of most of these has diminished over the years due to side effects, 
unfavorable pharmacokinetics, and drug resistance. Currently only 
three PIs, darunavir (DRV), lopinavir (LPV), and atazanavir (ATV) 
(Figure 1) – boosted with small doses of ritonavir (RTV) – are 
being used in cART as they have comparatively higher potency and 
better resistance profiles.2, 3
Most HIV-1 PIs are substrate-based peptidomimetics containing a 
hydroxyl group as a transition state mimetic and diverse moieties 
that target the S1/S1 and S2/S2 subsites of the enzyme.4, 5 Among 
the PIs in clinical use, DRV is the most potent with the highest 
barrier to resistance and efficacy against multidrug-resistant 
HIV-1 strains.6 The excellent potency and resistance profiles of 
DRV are attributed to the bis-tetrahydrofuran (bis-THF) moiety, 
which forms strong hydrogen bonding interactions with the main-
chain NH of Asp29 and Asp30 in the S2 subsite of the enzyme.7 
Moreover, the extensive van der Waals (vdW) interactions of the 
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bis-THF moiety, along with the sulfonamide-based Phe-Leu dipeptide 
isostere and the 4-aminobenzene group, also significantly 
contribute to the potency of DRV.8 Due to these unique binding 
characteristics, the P2 bis-THF moiety of DRV has emerged as a 
privileged ligand for targeting the S2 subsite of HIV-1 protease 
especially when incorporated into the (R)-
(hydroxyethylamino)sulfonamide isostere.9
Efforts to improve potency, pharmacokinetics, and resistance 
profiles of HIV-1 PIs have led to the discovery of exceptionally 
potent compounds exhibiting a wide range of properties.5, 10-14 In 
recent years, these efforts have focused mainly on exploring DRV 
analogues with similar sulfonamide-based dipeptide isosteres and 
P2/P2 moieties. Many analogues of DRV with modifications at P1/P1 
and P2/P2 positions have been explored extensively,5, 15-18 including 
novel bis-THF analogues showing improved hydrogen bonding and vdW 
interactions with the protease.19-22 Moreover, detailed structural 
analyses informing structure-based design of inhibitors with the 
DRV scaffold have been reported numerous times including recent 
structures determined by neutron crystallography.5, 7, 8, 23-25
However, very few inhibitors containing the bis-THF moiety in 
non-sulfonamide dipeptide isosteres have been explored.26-28 
Previously, Chen and colleagues at Abbott Laboratories explored 
PIs with bis-THF on either side of the pseudo-C2-symmetric Phe-Phe 
dipeptide isostere of LPV,26, 27 while Cannizzaro and coworkers at 
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Gilead Sciences designed similar analogues using the aza-dipeptide 
isostere of ATV.28 Although some of the Phe-Phe isostere-based 
compounds, such as 4 and 5 (Figure 1), exhibited significant 
antiviral activity against wild-type HIV-1, in the absence of 
direct comparison, it is unclear if their potency is similar to 
that of DRV.26 Also, due to limited structure-activity relationship 
studies, the S2/S2 subsite preference of the bis-THF moiety in the 
context of Phe-Phe isostere remains unclear,26, 27 as is the identity 
of an optimal moiety for targeting the opposite S2/S2 subsite.26 
Moreover, no cocrystal structures of such hybrid PIs have been 
reported, limiting opportunities for structure-guided design and 
optimization.
In this study, we investigate HIV-1 PIs containing the bis-THF 
moiety of DRV in the Phe-Phe dipeptide isostere of LPV with the 
aim to identify compounds with potency similar to that of DRV but 
with an alternate non-sulfonamide scaffold. Protease-inhibitor 
molecular interactions are characterized using X-ray 
crystallography and molecular dynamics (MD) simulations to aid 
structure-guided optimization of these hybrid PIs. In addition, 
interdependence of HIV-1 protease subsites is explored to provide 
insight into subsite preferences and influence of different 
inhibitor moieties on binding and potency. 
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Figure 1. Structures of HIV-1 protease inhibitors darunavir (DRV) 
(1), lopinavir (LPV) (2), atazanavir (ATV) (3), previously 
reported hybrid compounds 4 and 5, and new hybrid compounds 
designed by incorporating the bis-THF moiety of DRV into the 
pseudo-symmetric Phe-Phe dipeptide isostere of LPV at the P2 (12a–
h) or P2 position (15a–c), in combination with an ATV-like 
hydrophobic amino acid moiety at the P2 or P2 position, 
respectively. The canonical nomenclature is used to indicate the 
position of each inhibitor moiety.
The active site of HIV-1 protease exhibits subsite 
interdependence in substrate recognition and inhibitor binding,29, 
30 but this feature of the protease has rarely been considered in 
inhibitor design. While identifying optimal moieties for targeting 
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each of the subsites in the protease active site is important, 
understanding the subsite interdependence and selection of the 
best combination of moieties are also crucial to achieving higher 
potency especially against drug-resistant variants.19 The bis-THF 
moiety potentially can be incorporated in diverse dipeptide 
isosteres in combination with suitable ligands targeting the other 
subsites. Thus, a series of hybrid HIV-1 PIs were synthesized by 
incorporating the bis-THF moiety of DRV on either side of the 
pseudo-C2-symmetric Phe-Phe dipeptide isostere of LPV in 
combination with ATV-like hydrophobic P2/P2 ligands of varying 
size and shape (Figure 1). The hybrid PIs were tested for 
inhibitory activity against wild-type and two drug-resistant 
variants and for antiviral activity in cellular assays. We also 
determined high-resolution X-ray crystal structures of all 
designed hybrid compounds and previously reported PI 4 bound to 
wild-type HIV-1 protease and characterized the binding 
interactions of bis-THF in the context of Phe-Phe isostere. In 
addition, molecular dynamics simulations were utilized to assess 
the stability of protease-inhibitor interactions in solution. The 
comprehensive structural and dynamic analyses of hybrid PIs have 
provided insights into inhibitor binding and interdependence of 
protease subsites.
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The synthesis of hybrid PIs incorporating the bis-THF moiety at 
either the P2 or P2 position is outlined in Scheme 1. The required 
Phe-Phe dipeptide isostere core intermediate 7 was synthesized 
from phenylalanine following previously reported methods with 
minor modifications (see Supporting Information for details) 
(Haight, OPRD, 1999).31 Reaction of the dipeptide isostere 7 with 
bis-THF activated carbonate 8 in the presence of DIEA provided 
intermediate 9. Debenzylation of 9 using ammonium formate and 10% 
palladium on activated carbon in methanol gave the corresponding 
deprotected amine 10, which was subsequently coupled with the amino 
acid derivatives 11a–h using HATU and DIEA to provide the target 
compounds 12a–h with bis-THF at the P2 position. While N-
(methoxycarbonyl)-protected amino acid derivatives 11a and 11e 
were commercially available, intermediates 11b–d and 11f–h were 
prepared from the corresponding amino acids by reaction with methyl 
chloroformate under basic conditions following a reported 
procedure.32
The PIs 15a–c with the bis-THF at the P2 position were 
synthesized using a similar reaction sequence. Coupling of the 
dipeptide isostere 7 with acids 11a–c under HATU peptide coupling 
conditions gave the corresponding intermediates 13a–c. Catalytic 
debenzylation of compounds 13a–c followed by coupling with bis-
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THF activated carbonate 8 in the presence of DIEA provided the 
target compounds 15a–c. A pair of previously reported PIs 4 and 5 
containing the dimethylphenoxy acetate and bis-THF moieties as the 
P2 or P2 ligands in the Phe-Phe isostere were also synthesized 
using the same reaction sequences.  
Scheme 1. Synthesis of Protease Inhibitors Incorporating Bis-
Tetrahydrofurn in a Pseudo-Symmetric Phe-Phe Dipeptide Isostere
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Reagents and conditions: (a) K2CO3, KOH, BnCl, H2O, 100 °C, 5 h; 
(b) NaNH2, CH3CN, MTBE, 0 °C, 2 h, then BnMgCl (2 M in THF), RT, 
14 h; (c) NaBH4, MsOH, i-PrOH, EGDME, 0 °C, 12 h; (d) NaBH4, TEA, 
DMA, 0–15 °C, 2 h; (e) DIEA, CH3CN, RT, 24 h; (f) Pd/C, HCO2NH4, 
MeOH, 50 °C, 12 h; (g) N-(methoxycarbonyl)-capped amino acid, HATU, 
DIEA, DMF, RT, 4 h.
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We explored hybrid HIV-1 PIs containing the bis-THF moiety of DRV 
in the Phe-Phe isostere of LPV, with the goal to characterize the 
binding interactions of this P2 ligand in the context of a pseudo-
C2-symmetric dipeptide isostere. The bis-THF moiety was used in 
combination with diverse N-(methoxycarbonyl)-capped amino acid 
derivatives similar to the P2/P2 moiety of ATV to optimize hydrogen 
bonding and vdW interactions in both the S2 and S2 subsites of 
HIV-1 protease. To explore subsite preference for the bis-THF 
moiety, pairs of compounds were synthesized with the bis-THF moiety 
attached at either the P2 (12a–c) or P2 (15a–c) position with 
respect to the central hydroxyl group of the Phe-Phe isostere. 
Considering potential subsite interdependence, incorporating a 
relatively small and conformationally flexible moiety at the other 
P2/P2 position was expected to allow the bis-THF moiety to 
optimally interact with the backbone atoms in the S2/S2 subsite, 
likely improving overall inhibitor binding with the protease. 
Structure-activity relationships were explored by incorporating 
hydrophobic amino acids of varying size and shape to identify an 
optimal ligand for targeting the other S2/S2 subsite.
Enzyme Inhibition and Antiviral Assays. The potency of PIs was 
assessed using biochemical and antiviral assays. The enzyme 
inhibition constants (Ki) were determined against wild-type 
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protease and two drug-resistant variants (I84V and I50V/A71V) 
using a highly sensitive fluorogenic assay (Table 1).33 Both I50V 
and I84V are major protease inhibitor resistance mutations that 
reduce susceptibility to LPV and DRV. For a subset of compounds, 
antiviral potencies (EC50) were determined against wild-type HIV-
1 (NL4-3 strain) using a cell-based antiviral assay. LPV and DRV 
were used as controls in all assays.
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Table 1. Enzyme Inhibitory Activity and Antiviral Potency of Hybrid HIV-1 Protease Inhibitors 
Ki (nM)a EC50 (nM)bInhibitor Structure
WT I84V I50V/A71V WT
12a 0.018 ± 0.003 0.208 ± 0.014 0.273 ± 0.043 11
15a 0.013 ± 0.001 0.372 ± 0.021 0.072 ± 0.005 39
12b 46 ± 3 236 ± 39 484 ± 70 NT
15b 7.3 ± 0.5 191 ± 30 40 ± 3 NT
12c 0.235 ± 0.016 0.71 ± 0.10 2.35 ± 0.39 NT
15c 0.161 ± 0.011 1.18 ± 0.26 1.39 ± 0.12 NT
12d 0.019 ± 0.004 0.069 ± 0.013 0.073 ± 0.003 66
12e 0.074 ± 0.006 0.302 ± 0.022 0.295 ± 0.082 55
12f 0.571 ± 0.076 1.82 ± 1.50 1.66 ± 0.48 NT
12g 0.055 ± 0.004 0.198 ± 0.014 0.560 ± 0.094 70
12h 0.027 ± 0.004 0.091 ± 0.013 0.029 ± 0.003 240
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4 0.017 ± 0.002 0.069 ± 0.005 0.072 ± 0.002 38
5 0.037 ± 0.005 0.259 ± 0.055 NT 16
LPV < 0.005 0.051 ± 0.004 0.061 ± 0.011 12
DRV < 0.005 0.025 ± 0.006 0.075 ± 0.006 5
aEnzyme inhibition constants against wild-type HIV-1 protease and 
drug resistant variants; bAntiviral potency against wild-type HIV-
1; NT = Not Tested 
Compounds 12a and 15a, with the bis-THF moiety at the P2 and P2  
position, respectively, and the N-(methoxycarbonyl)-tert-leucine 
at the opposite P2/P2 position, showed excellent inhibitory 
potencies against wild-type protease and the drug resistant 
variants. Compared to DRV and LPV, both compounds were less active, 
particularly against the I84V variant. Interestingly, compounds 
12a and 15a exhibited similar Ki values, though the latter was 4-
fold more active against the I50V/A71V variant, indicating no clear 
S2/S2 subsite preference for the bis-THF moiety. However, in 
antiviral assays compound 12a was 3-fold more potent than 15a 
against wild-type HIV-1. The compound 12a, with the bis-THF moiety 
at the P2 position, exhibited excellent antiviral potency (EC50 = 
11 nM) comparable to that of LPV (EC50 = 12 nM) and DRV (EC50 = 5 
nM). A similar potency profile was observed for previously reported 
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compounds 4 and 5 containing the bis-THF and the dimethylphenoxy 
acetate moieties as the P2 and P2 ligands. Compound 5 exhibited 
2-fold better antiviral potency than 4, indicating a reverse 
subsite preference for the bis-THF moiety relative to the 12a/15a 
pair. The small variation in the antiviral potencies of compounds 
12a/15a and 4/5 indicate that the position of the bis-THF moiety 
with respect to the central hydroxyl group of the Phe-Phe isostere, 
though not critical for binding, may affect potency in cellular 
assays. 
Although the potency of the hybrid compounds was not particularly 
sensitive to the position of the bis-THF moiety, compounds with 
different hydrophobic amino acid derivatives at the opposite P2/P2 
position showed markedly different inhibitory potencies. The 
compounds with the cycloleucine moiety, 12b and 15b, were 
significantly less active (>2500-fold and 560-fold, respectively) 
than the corresponding tert-leucine analogues 12a and 15a. The 
dramatic loss of potency is likely due to the altered shape and 
flexibility of the hydrophobic amino acid moiety. This was further 
supported by the fact that the corresponding cyclopentylglycine 
analogues 12c and 15c, though also an order of magnitude less 
active than 12a and 15a, still exhibited sub-nanomolar to low nM 
potency against wild-type protease and drug-resistant variants. 
Together these data confirm that the hydrophobic amino acid moiety 
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at the opposite P2/P2 position significantly influence potency in 
both biochemical and antiviral assays.
Since potency of the compounds with bis-THF moiety attached to 
the Phe-Phe isostere largely depended on the hydrophobic amino 
acid moiety at the opposite side of the core scaffold, we 
investigated size and shape requirements for optimally targeting 
the S2 subsite. Analogues of compound 12a were synthesized with 
diverse hydrophobic amino acid derivatives as P2 ligands while 
keeping the bis-THF moiety at the P2 position. The alanine analogue 
12d exhibited excellent inhibitory potency with Ki values against 
resistant variants comparable to that of LPV and DRV. The 
corresponding valine analogue 12e was 4-fold less active against 
wild-type protease but maintained similar inhibitory potency as 
12a against the resistant variants. However, compared to 12a 
compounds 12d and 12e were 6- and 5-fold less active in antiviral 
assays, respectively, indicating that factors other than binding 
affinity are responsible for lower antiviral potency. The 
cyclopropyl analogue 12f was considerably less active than 12a, 
with Ki values similar to the cyclopentyl analogue 12c, strongly 
suggesting that cyclic moieties at the P2/P2 position are 
unfavorable. Replacement of tert-leucine with an isoleucine 
(compound 12g) or alloisoleucine (compound 12h) moiety at the P2 
position also resulted in slightly lower activity against wild-
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type protease but similar or better potency against resistant 
variants. This further confirmed earlier findings that the P2/P2 
group opposite to the bis-THF moiety on the Phe-Phe core has a 
significant impact on potency. These results are in contrast to 
the sulfonamide-based dipeptide isostere of DRV, where diverse P2 
modifications result in relatively minor changes in potency.6 The 
identity of the P2/P2 moiety opposite to the bis-THF on the Phe-
Phe core considerably impacts potency in both biochemical and 
antiviral assays.
Analysis of Protease-Inhibitor Complexes. To characterize 
protease-inhibitor molecular interactions, twelve high-resolution 
(1.8–2.0 Å) crystal structures of hybrid PIs and compound 4 bound 
to wild-type HIV-1 protease of the NL4-3 strain were determined. 
A cocrystal structure of LPV was also determined bound to the same 
protease enzyme for direct comparison. The crystallographic data 
collection and refinement statistics are summarized in Table S1. 
Following convention, protease chains were assigned chain A (non-
prime) or chain B (prime) depending on the interactions between 
the central hydroxyl group of the Phe-Phe isostere and the 
catalytic aspartates Asp25/Asp25.
LPV and DRV achieve low picomolar affinity to wild-type HIV-1 
protease by making a number of hydrogen bonds and vdW interactions 
with the active site residues (Figure S1). The interactions of the 
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transition state mimetic secondary hydroxyl group with the 
catalytic aspartates, together with the vdW interactions of the 
adjacent P1/P1 moieties, are critical for overall inhibitor 
binding. Together these interactions determine the positions of 
the P2/P2 moieties in the active site, which in turn determine 
the patterns of hydrogen bonding and vdW interactions of these 
moieties with the protease. DRV contains a sulfonamide-based Phe-
Leu dipeptide isostere core with the (R)-configuration of the 
secondary hydroxyl group, whereas LPV has a pseudo-C2-symmetric 
Phe-Phe dipeptide isostere with the (S)-configuration of the 
hydroxyl group. Though chemically quite distinct, the core 
scaffolds of LPV and DRV make largely similar hydrogen bonding and 
vdW interactions with the protease. These inhibitors, however, 
differ in their interactions with the protease in the S2 and S2 
subsites.
The bis-THF moiety of DRV forms direct hydrogen bonds with the 
main-chain NH of Asp29 and Asp30 in the S2 subsite, while the 4-
aminobenzene makes a direct hydrogen bond with the main-chain 
carbonyl of Asp30 as well as a water-mediated interactions with 
the side-chain carboxylate of the same residue in the S2 subsite 
(Figure S1). The cyclic urea moiety of LPV makes direct hydrogen 
bonds with the main-chain NH and side-chain carboxylate of Asp29. 
The same moiety also makes water-mediated interactions with the 
Page 18 of 83
ACS Paragon Plus Environment






























































main-chain carbonyl of Gly27 and the side-chain carboxylate of 
Asp29 in the S2 subsite. However, in contrast to the P2 moiety of 
DRV, the dimethylphenoxy acetate moiety of LPV only makes 
hydrophobic interactions in the S2 subsite (Figure S1). The hybrid 
compounds combine the pseudo-C2-symmetric Phe-Phe isostere of LPV 
with the bis-THF moiety of DRV and an ATV-like amino acid moiety 
to enhance direct hydrogen bonding and vdW interactions in the S2 
and S2 subsites.
The cocrystal structures of hybrid compounds revealed similar 
binding conformations of the Phe-Phe isostere and the bis-THF 
moiety as observed in the protease complexes with LPV and DRV, 
respectively (Figure 2). Importantly, the bis-THF moiety is 
positioned to interact with the main-chain NH of residues Asp29 
and Asp30, mimicking the binding interactions of DRV (Figure 3). 
This binding conformation is maintained in all hybrid compounds 
including 4 regardless of the position of the bis-THF moiety. As 
a result, within each compound series (with the bis-THF moiety at 
the P2 and P2 position respectively), the structures aligned well 
with variations occurring only at the hydrophobic amino acid moiety 
(Figure 4).
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Compound 12a Compound 15a Compound 4
Figure 2. Overlays of protease cocrystal structures bound to LPV 
(PDB 6PJB) (grey, top) and DRV (6DGX) (brown, bottom) with 
compounds 12a (bis-THF at P2; PDB 6PJD) (green), 15a (bis-THF at 
P2′; PDB 6PJM) (orange), and 4 (PDB 6PJC) (salmon) revealed similar 
binding conformations of the Phe-Phe isostere and the bis-THF 
moiety as observed in the protease complexes with LPV and DRV, 
respectively. Note that DRV is flipped 180º to compare with bis-
THF of 15a at the P2′ position.
In all complexes, the central hydroxyl group of the Phe-Phe core 
maintains the key hydrogen bonds with the side-chain carboxylates 
of the catalytic residues Asp25/Asp25. Nevertheless, subtle 
differences in hydrogen bonding and vdW interactions were observed 
between the Phe-Phe cores in LPV and the hybrid compounds. Notably, 
one of the four water-mediated interactions with the flap residue 
Ile50 is consistently longer (2.9–3.4 Å) than what is observed in 
the LPV structure (2.7 Å) (Table S2). The two amide NH groups on 
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each side of the Phe-Phe core could potentially interact with the 
backbone carbonyl of Gly27 and Gly27′, but in the LPV structure 
only the Gly27 is close enough to form a hydrogen bond (2.9 Å 
versus 3.9 Å) (Figure 3). This phenomenon is also observed in the 
protease complex with compound 4 (2.9 Å versus 3.7 Å) indicating 
that the large hydrophobic P2′ moiety prevents the additional 
hydrogen bond from occurring with Gly27′. In contrast, in all hybrid 
compound structures the core NH groups are within 3.5 Å from the 
backbone carbonyls of Gly27 and Gly27′ (Table S2), although 
simultaneous interactions with both Gly27/Gly27 may not be stable. 
Nevertheless, the combination of bis-THF and a flexible, 
hydrophobic amino acid moiety allow both core NH groups to interact 
with the main-chain carbonyls of residues Gly27/Gly27′.
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P2 P2′ P2 P2′
P2 P2′ P2 P2′
Figure 3. Crystal structures of wild-type HIV-1 protease in complex 
with LPV (PDB 6PJB) (A) and hybrid compounds 4 (PDB 6PJC) (B), 12a 
(PDB 6PJD) (C), and 15a (PDB 6PJM) (D). The bis-THF moiety 
maintains the hydrogen bonding interactions with the main-chain NH 
of Asp29/Asp29 and Asp30/Asp30 in the S2/S2 subsites regardless 
of the its position on the Phe-Phe core. Hydrogen bonds and water-
mediated interactions as determined by PyMol are shown as black 
dashed lines with waters shown as red spheres.
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Figure 4. Superposition of HIV-1 protease complexes with compounds 
12a–12h (A) and compounds 15a–15c (B), showing similar binding 
conformations of the bis-THF moiety regardless of the position and 
minor differences at the Phe-Phe isostere, but major differences 
at the P2/P2 amino acid moiety. The protease active site is shown 
in a ribbon representation, with bound inhibitors depicted as 
sticks.
The Phe-Phe isostere in hybrid compounds, in addition to 
maintaining key hydrogen bonding interactions with the protease, 
makes a number of favorable vdW interactions with the hydrophobic 
residues that make up the S1/S1 subsites. Despite the same 
phenylalanine side chains at the P1 and P1 positions, there are a 
few notable differences in vdW contacts with the protease (Figure 
S2). Compared to LPV, the P1/P1 phenyl group adjacent to the amino 
acid moiety is shifted towards Val82 resulting in improved vdW 
contacts with that residue, particularly for compounds with larger 
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P2/P2 amino acid moieties. These localized gains in vdW contacts 
are slightly lower for compounds 15a–c with bis-THF at the P2 
position than their corresponding analogues 12a–c. The shift of 
the P1/P1 phenyl group towards Val82, creating more vdW contacts, 
resulted in a nearly equal and opposite loss of contacts with Ile50 
in the same subsite. The packing of the phenyl group adjacent to 
the bis-THF moiety resulted in a small increase in vdW contacts 
with the 80’s loop (residues 81, 82 and 84) but decrease in 
contacts with flap residue Gly49. For compounds 15a–c, gains in 
vdW contacts are smaller and the losses are greater. Overall, 
despite localized losses and gains in vdW interactions for both 
series of compounds, the packing of the P1 and P1 groups remain 
generally similar to LPV.
The cocrystal structures of hybrid compounds (and 4) also 
revealed similar binding interactions of the bis-THF moiety as in 
DRV-protease complex regardless of the position, with the two ring 
oxygen atoms positioned to form hydrogen bonds with the main-chain 
NH of Asp29 and Asp30. However, there are subtle differences in 
the position and puckering of the bis-THF rings, causing the 
carbamate-linked THF ring oxygen atom to slightly shift away from 
the backbone NH of Asp30 compared to DRV (3.1–3.4 Å versus 2.9 Å) 
(Figure 5). Whereas the oxygen atom of the other THF ring maintains 
a similar distance to the backbone NH of Asp29 (2.7–2.9 Å versus 
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2.8 Å) (Table S2). For compounds 12a–c, these subtle changes in 
the bis-THF moiety arise from the differences in the binding of 
core isosteres, where the P1 benzyl group and the carbamate are 
shifted towards the B-chain compared to their position in DRV. 
This is likely due to the additional carbon in the core or to 
accommodate the larger P1 group. In compounds 15a–c, the core 
scaffold from the central hydroxyl to the bis-THF moiety is 
identical. However, the opposite stereochemistry of the central 
hydroxyl causes a subtle shift preventing the bis-THF moiety from 
optimally interacting with Asp30′ (Figure 5). Despite these minor 
differences in the position of the bis-THF moiety, the hybrid 
compounds make similar hydrogen bonding interactions with the 
protease in the S2/S2′ subsite compared to DRV.
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Figure 5. Comparison of the binding conformations of the bis-THF 
moiety and protease-inhibitor intramolecular distances with the 
main-chain NH of Asp29 and Asp30 in the S2/S2′ subsite of HIV-1 
protease. As observed in the DRV-protease complex (PDB 6DGX), the 
bis-THF moiety retained similar interactions with the protease in 
complexes with compound 4 (PDB 6PJC) (top), the most potent hybrid 
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compounds 12a (PDB 6PJD) and 15a (PBD 6PJM) (middle), and the least 
potent hybrid compounds 12b (PDB 6PJE) and 15b (PDB 6PJN) (bottom), 
irrespective of position on the Phe-Phe core.
The bis-THF moiety of DRV is critical to its potency, not only 
for the hydrogen bonding interactions with Asp29 and Asp30, but 
also vdW packing with residues in the S2 subsite, particularly 
Val32 and Ile47. In hybrid compounds, the minor change in the 
position and puckering of the bis-THF moiety causes reduced vdW 
interactions with Ala28 and Asp30, but increased interactions with 
Ile47 and Gly48 (Figure S3). The main-chain carbonyl of Gly48 is 
oriented towards the hydrophobic region of bis-THF, so enhanced 
contacts with this residue may be unfavorable. In contrast, 
compounds 4, 15a and 15b do not make these unfavorable contacts 
with Gly48. With the exception of enhanced interactions with Ile47, 
the bis-THF moiety in most hybrid compounds make less optimal vdW 
interactions with the protease compared to those of DRV.
The major difference between the hybrid compounds and the 
previously reported Phe-Phe core-based bis-THF containing PIs 4 
and 5 is the introduction of an ATV-like amino acid moiety to 
target the opposite S2/S2 subsite. The amino acid side chain 
interacts with hydrophobic protease residues, while the N-
(methoxycarbonyl)-capping group allows for additional hydrogen 
bonding interactions with the protease. As already noted, LPV’s 
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P2′ moiety does not form any hydrogen bonds, and DRV’s P2′ moiety 
makes one direct and one water-mediated interactions in the S2′ 
subsite (Figure S1). In most hybrid compounds, the carbonyl oxygen 
of the carbamate makes one direct hydrogen bond with the backbone 
NH of Asp29 (Asp29), and the carbamate NH makes another direct 
hydrogen bond with the backbone carbonyl of Gly48 (Gly48) in the 
flaps (Figure 6). There are also a number of coordinated water 
molecules that allow for additional water-mediated interactions. 
The carbonyl oxygen of the carbamate coordinates the same water-
mediated interactions as the cyclic urea moiety of LPV, with the 
backbone carbonyl of Gly27 (Gly27) and the side-chain carboxylate 
of Asp29 (Asp29) (Figure 6). This network of polar interactions 
is maintained by all amino acid moieties in both the S2′ and S2 
subsites except the cycloleucine in compound 12b.
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Figure 6. Comparison of protease-inhibitor direct hydrogen bonds 
and water-mediated interactions in the S2/S2 subsites for the 
cyclic urea moiety of LPV (PDB 6PJB) (A), N-(methoxycarbonyl)-
tert-leucine of ATV (PDB 3EKY) (B), and the N-(methoxycarbonyl)-
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capped amino acid moieties of hybrid compound 15a (PDB 6PJM) (C), 
12a (PDB 6PJD) (D),  15b (PDB 6PJN) (E), and 12b (PDB 6PJE) (F). 
Polar interactions are shown as black dashed lines (as determined 
by PyMol) with waters shown as red spheres. 
The carbamate of compound 12b is flipped relative to all other 
inhibitors losing the direct hydrogen bond to flap residue Gly48′ 
(Figure 6F). This flip positions the carbonyl oxygen of the 
carbamate close to the carbonyl oxygen of Gly48′ (3.3 Å), creating 
a very unfavorable interaction and preventing compound 12b from 
utilizing the same water-mediated interactions as LPV and most 
hybrid compounds. Instead 12b forms a hydrogen bond with a 
“backside” water in the S2′ subsite, creating a water-mediated 
interaction with the main-chain carbonyl and NH of Asp30′ (Figure 
6F). The marked changes in the hydrogen bonding interactions in 
the S2/S2 subsite likely underlie the greatly reduced potency of 
12b compared to all other hybrid compounds. Unlike 12b, the P2 
carbamate group in compound 15b maintained a similar conformation 
as in the tert-leucine analogue 15a but with a slight change in 
the position of the carbonyl oxygen away from Asp29. This shift 
resulted in increased hydrogen bond distance between the P2 
carbamate carbonyl and the main-chain NH of Asp29 compared to 15a 
(3.3 Å versus 2.9 Å). However, the reduced potency of 15b could 
not result from minor differences in hydrogen bonding interactions 
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alone, highlighting the significance of non-polar interactions for 
potency. 
The protease-inhibitor vdW interactions in the S2/S2′ subsite 
varied significantly depending on the size and shape of the 
hydrophobic amino acid moiety (Figure S4). Compounds 12a and 15a 
with the tert-leucine make highly distributed vdW contacts with a 
number of residues. In contrast, compared to tert-leucine, the 
cycloleucine side chain in 12b predominantly interacts with Ile50 
and I84V, while losing significant contacts with residues 28–30 
(Figure 7). The cycloleucine side chain of 15b packs in the same 
hydrophobic area but makes less vdW contacts than 12b. Compound 
12c with cyclopentyl glycine also has enhanced vdW contacts with 
Ile50 but without experiencing losses at other resides as observed 
for 12b. In general, the cyclic hydrophobic amino acid derivatives 
make more localized vdW interactions in the S2/S2′ subsite while 
the acyclic moieties make more distributed contacts. Thus, in 
addition to altered polar interactions, the differences in vdW 
contacts due to the size and shape of the hydrophobic amino acid 
moiety are likely responsible for the varied inhibitor potencies.
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Figure 7. Comparison of binding conformation (A) and van der Waals 
packing with residues in the S2′ subsite for the most and least 
potent inhibitors 12a (PDB 6PJD) (B, green sticks) and 12b (PDB 
6PJE) (C, blue sticks). Compound 12a makes more extensive contacts 
with the protease as estimated by relative vdW contact energy 
compared to 12b (–91 versus –86 kcal/mol), with major difference 
occurring at the S2′ subsite (–27 versus –23 kcal/mol). Protease 
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residues are colored red to blue for highest to lowest vdW 
interactions with the inhibitor. 
Molecular Dynamics (MD) Simulations. Starting from the cocrystal 
structures, molecular dynamics (MD) simulations were utilized to 
interrogate the stability of protease-inhibitor interactions in 
the dynamic ensemble of the complexes. Three replicates of fully 
hydrated 100 ns MD simulations were performed on each protease-
inhibitor complex. All simulations reached convergence (Figure 
S5).
The protease active site and flaps dynamics were analyzed by 
measuring Cα distances between specific residues. The analysis 
focused on the most and least potent pairs of compounds containing 
bis-THF at either the P2 or P2′ position (12a/15a and 12b/15b) 
compared to LPV. The cocrystal structures suggested the flaps and 
the 80’s loops surrounding the inhibitor may be perturbed when 
bound to different compounds. To monitor dynamics of the flaps, 
distance distributions between Cα atoms of Ile50–Ile84′, Ile50′–
Ile84 and Ile50–Ile50′ were calculated during the MD trajectories. 
Distances for Ile84–Ile84′ and Pro81–Pro81′ were used to probe the 
expansion or narrowing of the “lower” and “upper” side wall of the 
active site, respectively (Figure S6). In protease complexes with 
hybrid compounds, the active site remained largely unchanged in 
the “lower” part of the active site as indicated by a single, 
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narrow distribution of Ile84–Ile84′ distance centered around 15.2 
Å. However, compared to LPV the shift in the Pro81–Pro81′ distance 
distribution with compounds 12a, 15a, 12b, and 15b indicated the 
active site was narrower in the “upper” portion close to the flaps. 
In addition, the active site was asymmetrically longer (Ile50′–
Ile84 or Ile50–Ile84′), sampling bimodal distance distributions, 
suggesting the sampling of a semi-open conformation of the flaps. This was supported 
by the Ile50–Ile50′ distance distribution, with one major peak around 5.3 
Å (closed flaps) and another 10 Å corresponding to semi-open flaps 
with compounds 15a and 15b (Figure S6). Increased distance between 
residues Ile50 and Ile50′ in the relatively short time 
(nanoseconds) during MD simulations has been previously suggested 
to indicate flap opening.34, 35 Thus, perturbed flaps dynamics and 
narrowing of the active site may indicate unfavorable binding of 
these compounds compared to LPV, which is supported by the Ki data.
Next, the stability of inhibitor binding was analyzed by 
calculating root-mean-square fluctuations (RMSF) of each atom 
(Figure 8). In all complexes, the bis-THF moiety often displayed 
the lowest RMSF amongst all moieties, regardless of its position 
on the Phe-Phe core. Notably, even in the least active compounds 
with nanomolar potency (12b and 15b), the bis-THF moiety showed 
fluctuations similar to that observed in 12a and 15a. Moreover, 
the phenylalanine side chain adjacent to the bis-THF moiety 
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displayed lower RMSF compared to the distal phenylalanine side 
chain, despite the pseudo-symmetric nature of the Phe-Phe core. 
The P2/P2′ amino acid moieties showed varying RMSF profiles, 
independent of the size or shape of the hydrophobic side chain. 
The phenylalanine adjacent to the amino acid moiety consistently 
displayed greater RMSF, with the exception of 12e. The varying 
fluctuations of the P1/P1′ moiety depending on the size and shape 
of the P2/P2′ moiety indicate interdependence between the S1/S1′ and 
S2/S2′ subsites. The P2/P2′ amino acid moiety also affected the 
fluctuations of the bis-THF moiety but to a much lesser extent. This data 
suggests that in hybrid compounds the bis-THF moiety and the 
adjacent P1/P1′ moiety remain relatively stable in the protease 
active site regardless of the position on the Phe-Phe core. In 
contrast, the fluctuations of the amino acid and the adjacent 
P1/P1′ moieties appear to destabilize overall inhibitor binding. 
Thus, due to interdependence between the S1/S1′ and S2/S2′ subsites, 
the optimization of the bis-THF containing hybrid PIs, would 
require modification of the amino acid moiety together with the 
adjacent P1/P1′ group.
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Figure 8. Inhibitor root-mean-square fluctuation (RMSF) of each 
non-hydrogen atom of DRV, LPV, and hybrid compounds mapped onto 
their crystal structure. Warmer colors indicate larger 
fluctuations.
The relationship between inhibitor and protease conformational 
dynamics was examined via simultaneous monitoring of inhibitor 
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bond rotations and protease residue distances. The dihedral angles 
of all inhibitor rotatable bonds were calculated throughout the MD 
simulations. Given the bimodal sampling of the flap distances 
(Ile50–Ile50′, Ile50–Ile84′ and Ile50′–Ile84), we examined whether 
the semi-open conformation of flaps was associated with certain 
inhibitor bond rotations. In protease complexes with compounds 12a 
and 15a, the two most potent inhibitors, the separation of the 
flap tips (Ile50–Ile50′) was associated with the conformational 
sampling of the dihedral controlling the amino acid moiety (Figure 
9). In this semi-open flap conformation, the Ile50/Ile50′ residues at 
the top of the flaps also lost intra-protease vdW contacts with residues 32, 47–49 and 84 (Figure 
S7). Loss of intra-protease vdW interactions could result in a less stable protease-inhibitor 
complex, leading to an overall decrease in inhibitor binding affinity.
In addition, protein dynamics were compared by calculating the 
root-mean-square fluctuations (RMSF) of Cα atoms. Consistent with 
our observations from the distance distributions, there were 
significant increases in fluctuations at the flaps and 80’s loop 
(Figure S8). In complex with LPV, the flaps and active site show 
little fluctuations, comparable to DRV. However, compounds 
containing bis-THF at the P2′ position showed increased 
fluctuations at both flaps, with fluctuations asymmetrically 
greater at the B chain flap, contacting the amino acid moiety. The 
increased protein fluctuation could impact the stability of 
protease-inhibitor hydrogen bonding interactions.
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Figure 9. The dihedral angle (φ5) responsible for conformational 
sampling of the tert-leucine moiety on  12a (A) and 15a (B) is 
associated with increased Ile50–Ile50′ distance sampling.
In the cocrystal structures, the hybrid compounds make a number 
of direct and water-mediated interactions with the protease active 
site, including the central hydroxyl with catalytic residues, coordinated water with Ile50/50′, 
the Phe-Phe core nitrogen atoms with Gly27, bis-THF with Asp29 and Asp30, carbamate with 
Asp29 and Gly48, and the coordinated S3′ water with Gly27′ and Asp29′. To assess if the 
increased protein and ligand fluctuations impact hydrogen bonding 
stability, the patterns and frequencies of these hydrogen bonds 
were monitored throughout the MD simulations (Figure 10, Figure 
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S9). In MD simulations, LPV and the hybrid compounds did not 
maintain all hydrogen bonds observed in the cocrystal structures. 
LPV and all compounds with bis-THF at the P2 position (4 and 12a–h) 
maintained a hydrogen bond with Asp25′ (66–99% frequency) but did 
not form a hydrogen bond with Asp25. Whereas compounds 15a and 15b 
containing bis-THF at the P2 position formed the hydrogen bonds 
with Asp25 and Asp25′ at roughly 100% and 50% frequency, 
respectively. In contrast, the hydrogen bond between compound 15c 
and Asp25 was unstable, while the hydrogen bond with Asp25′ was highly 
stable (92% frequency). Hybrid compounds maintained the network of 
water-mediated interactions with the main-chain NH of Ile50 and 
Ile50′ at varying stability. The interactions with Ile50 were 
observed to be less stable compared to the ones with Ile50′ (21–
65% versus 49–78%). For most of the hybrid compounds, the hydrogen 
bonds between the Phe-Phe core NH groups and the main-chain 
carbonyls of Gly27/Gly27′ were either not observed or were very unstable. 
The bis-THF moiety in all hybrid compounds maintained two 
hydrogen bonds with the main-chain NH of Asp29/Asp29′ and 
Asp30/Asp30′ at high frequency, regardless of the position on the 
Phe-Phe isostere (Figure 10, Figure S9). In contrast, the P2/P2′ amino 
acid moiety had varying effects on hydrogen bonding interactions 
in the S2/S2′ subsite. The carbamate nitrogen of hybrid compounds 
formed a hydrogen bond with the backbone carbonyl of Gly48′ at 
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moderate to high frequency, but this interaction was not observed 
for the least potent compound 12b and was less stable for 15b. The 
carbonyl oxygen of the P2′ amino acid moiety in compounds 12a and 
12c formed relatively stable water-mediated interactions with the 
sidechain of Asp30′. In contrast, the carbonyl oxygen of the P2 
moiety in compounds 15a and 15c formed three low-frequency (14–
39%) water-mediated interactions, bridging the main-chain carbonyl 
of Gly27 and the side-chain carboxylate of Asp29. These data suggest that 
for most hybrid compounds the key hydrogen bonding interactions of the bis-THF moiety and the 
Phe-Phe isostere with protease remain relatively stable. In addition, the size and shape of the P2/P2′ 
amino acid moiety not only influences the interactions in the S2/S2′ subsites but can also propagate 
changes in the water-mediate interactions between the inhibitors and Ile50/Ile50′.
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Figure 10. Protease-inhibitor hydrogen bond frequencies from MD 
simulations mapped onto the cocrystal structures of compounds  12a 
(A), 12b (B), 15a (C), and 15b (D). The protease side chains and 
inhibitors are shown as sticks; chains A and B are colored cyan 
and magenta, respectively.
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We have explored hybrid HIV-1 PIs containing the bis-THF moiety 
of DRV on either side of the Phe-Phe dipeptide isostere of LPV to 
ascertain whether this moiety could maintain key interactions with 
the protease and improve potency against wild-type and primary 
drug-resistant variants of the enzyme. Most of the hybrid compounds 
retained picomolar biochemical potency irrespective of the 
position of bis-THF relative to the central hydroxyl group, likely 
due to the pseudo-C2-symmetric nature of the Phe-Phe isostere. But 
in both compound series the identity of the other P2/P2 moiety 
significantly affected potency, favoring relatively flexible, 
hydrophobic moieties. The cocrystal structures of hybrid compounds 
revealed that the bis-THF moiety maintains the key hydrogen bonding 
interactions with the protease in the S2/S2 subsite as observed 
in the DRV-protease complex regardless of its position on the Phe-
Phe isostere. In contrast, the binding of the hydrophobic amino 
acid moiety in the other S2/S2 subsite was greatly influenced by 
the size, shape, and flexibility of the hydrophobic group, which 
affected hydrogen bonding and vdW interactions with the protease. 
Moreover, this moiety appears to influence binding of the adjacent 
P1/P1′ group as well as the water-mediated interactions between the inhibitor and flap 
residues, indicating dynamic interdependence between the protease subsites. 
This is further supported by the relatively stable binding 
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interactions of the bis-THF moiety and the adjacent P1/P1′ group. 
The dynamic interdependence between subsites in the protease 
active site can be exploited to optimize inhibitor potency against drug-
resistant protease variants. The detailed structural 
characterization of hybrid HIV-1 PIs containing bis-THF in non-
sulfonamide dipeptide isosteres offers opportunities for 
structure-guided optimization of these promising inhibitors. 
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General. All reactions were performed in oven-dried round-bottom 
flasks fitted with rubber septa under argon atmosphere unless 
otherwise noted. All reagents and solvents, including anhydrous 
solvents, were purchased from commercial sources and used as 
received. Flash column chromatography was performed on an 
automated Teledyne ISCO CombiFlash Rf+ system equipped with a UV-
vis detector using disposable Redisep Gold high performance silica 
gel columns or was performed manually using silica gel (230−400 
mesh, EMD Millipore). Thin- layer chromatography (TLC) was 
performed using silica gel (60 F254) coated aluminum plates (EMD 
Millipore), and spots were visualized by exposure to ultraviolet 
light (UV), exposure to iodine adsorbed on silica gel, and/or 
staining with alcohol solutions of phosphomolybdic acid (PMA) and 
ninhydrin followed by brief heating. 1H NMR and 13C NMR spectra 
were acquired on Varian Mercury 400 MHz and Bruker Avance III HD 
500 MHz NMR instruments. Chemical shifts are reported in ppm (δ 
scale) with the residual solvent signal used as a reference and 
coupling constant (J) values are reported in hertz (Hz). Data are 
presented as follows: chemical shift, multiplicity (s = singlet, 
d = doublet, dd = doublet of doublet, dd = doublet of triplet, t 
= triplet, m = multiplet, br s = broad singlet), coupling constant 
in Hz, and integration. High-resolution mass spectra (HRMS) were 
recorded on a Thermo Scientific Orbitrap Velos Pro mass 
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spectrometer coupled with a Thermo Scientific Accela 1250 UPLC and 
an autosampler using electrospray ionization (ESI) in the positive 
mode. The purity of final compounds was determined by analytical 
HPLC and was found to be ≥95% pure. HPLC was performed on a Agilent 
1200 system equipped with a multiple wavelength detector and a 
manual injector under the following conditions: column, Phenomenex 
Hypersil-BDS-5u-C18 (5 μm, 4.6 mm × 250 mm, 130 Å); solvent A, H2O 
containing 0.1% trifluoroacetic acid (TFA); solvent B, CH3CN 
containing 0.1% TFA; gradient, 20% B to 100% B over 15 min followed 
by 100% B over 5 min; injection volume, 20 μL; flow rate, 1 mL/min. 
The wavelengths of detection were 254 nm and 280 nm. Retention 
times and purity data for each target compound are provided in the 
Experimental Section.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-5-
(dibenzylamino)-4-hydroxy-1,6-diphenylhexan-2-yl)carbamate (9). A 
solution of the Phe-Phe core intermediate 7 (3.00 g, 6.46 mmol) in 
anhydrous CH3CN (50 mL) was cooled to 0 °C and treated with 
diisopropylethylamine (DIEA) (3.37 mL, 19.35 mmol) followed by 
bis-THF activated carbonate 8 (1.93 g, 7.10 mmol). The reaction 
mixture was warmed to room temperature and stirred for 24 h, 
concentrated under reduced pressure and dried under high vacuum. 
The residue was purified by flash column chromatography (RediSep 
Gold, 80 g, gradient elution with 0–100% ethyl acetate/hexanes) to 
provide the intermediate 9 (4.01 g, 100%) as a white solid. 1H NMR 
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(500 MHz, CDCl3) δ 7.34–7.17 (m, 16 H), 7.10 (d, J = 7.5 Hz, 2 H), 
7.01 (d, J = 7.0 Hz, 2 H), 5.69 (d, J = 5.0 Hz, 1 H),  5.29 (d, J 
= 6.0 Hz, 1 H),  5.12 (q, J = 6.5 Hz, 1 H), 4.52 (br s, 1 H),  4.02 
(dd, J = 9.0, 7.0 Hz, 1 H), 3.95–3.73 (m, 6 H), 3.65–3.58 (m, 1 
H), 3.38 (d, J = 13.0 Hz, 2 H),  3.10 (dd, J = 14.0, 5.5 Hz, 1 H),  
3.04–2.97 (m, 1 H), 2.85–2.76 (m, 2 H), 2.66 (dd, J = 13.0, 6.5 
Hz, 1 H), 2.54 (dd, J = 14.5, 7.0 Hz, 1 H), 1.87–1.75 (m, 2 H), 
1.52 (dd, J = 14.5, 3.5 Hz, 1 H), 1.11 (dt, J = 14.5, 8.5 Hz, 1 H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 155.41, 140.15, 138.74, 138.18, 
129.61, 129.15, 128.86, 128.69, 128.40, 127.53, 126.47, 126.40, 
109.48, 73.00, 71.03, 69.77, 69.74, 64.31, 53.95, 52.28, 45.49, 
41.35, 38.15, 32.15, 26.09 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C39H45N2O5, 621.3323; found 621.3306.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-((S)-2-((methoxycarbonyl)amino)-3,3-
dimethylbutanamido)-1,6-diphenylhexan-2-yl)carbamate (12a). A 
solution of compound 9 (0.50 g, 0.81 mmol) in anhydrous MeOH (10 
mL) was treated with ammonium formate (0.30 g, 4.83 mmol) and 10% 
Pd/C (0.1 g) and the reaction mixture was stirred at 50 °C for 14 
h. The reaction mixture was filtered through a pad of Celite and 
the filtrate was concentrated under reduced pressure. The 
resulting deprotected amine 10 was dissolved in anhydrous CH2Cl2 
(10 mL) and the solution was cooled to 0 °C. N-(methoxycarbonyl)-L-
tert-leucine 11a (0.18 g, 0.97 mmol), DIEA (0.280 ml, 1.61 mmol) 
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and HATU (0.48 g, 1.26 mmol) were added. The reaction mixture was 
stirred at room temperature for 16 h, concentrated under reduced 
pressure, and dried under high vacuum. The residue was purified by 
flash column chromatography (RediSep Gold, 24 g, gradient elution 
with 0–15% methanol/dichloromethane) to provide the target 
compound 12a (0.27 g, 55%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.25–7.13 (m, 8 H), 7.07 (d, J = 7.0 Hz, 2 H), 6.57 (d, J 
= 9.0 Hz, 1 H), 5.65 (d, J = 5.0 Hz, 1 H), 5.46 (d, J = 9.0 Hz, 1 
H), 5.12 (d, J = 8.0 Hz, 1 H), 5.04 (q, J = 6.5 Hz, 1 H), 4.15 (q, 
J = 7.0 Hz, 1 H), 4.06–3.96 (m, 1 H), 3.93 (dd, J = 9.5, 6.5 Hz, 
1 H), 3.87–3.63 (m, 4 H), 3.66 (s, 3 H, overlapping), 2.96–2.81 
(m, 3 H), 2.80 (s, 2 H), 2.66 (dd, J = 14.0, 7.5 Hz, 1 H), 1.74–
1.55 (m, 4 H), 0.93 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 170.93, 
157.18, 155.58, 137.95, 137.39, 129.39, 128.67, 128.60, 126.82, 
126.60, 109.44, 73.47, 70.97, 69.74, 69.67, 63.44, 54.83, 52.59, 
50.95, 45.51, 41.72, 40.19, 38.35, 34.21, 26.71, 26.02 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C33H46N3O8, 612.3280; found 612.3276; 
Anal. HPLC: tR 10.86 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-(1-((methoxycarbonyl)amino)cyclopentane-1-
carboxamido)-1,6-diphenylhexan-2-yl)carbamate (12b). The same 
procedure was used as described above for compound 12a. Compound 
9 (1.00 g, 1.61 mmol) was treated with ammonium formate (0.61 g, 
9.66 mmol) and 10% Pd/C (0.25 g) to give the corresponding 
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deprotected amine 10, which was coupled with N-(methoxycarbonyl)-
cycloleucine 11b (0.36 g, 1.93 mmol) using DIEA (1.12 ml, 6.44 
mmol) and HATU (0.96 g, 2.51 mmol) to provide the target compound 
12b (0.66 g, 67%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.28–
7.22 (m, 4 H), 7.21–7.16 (m, 4 H), 7.14 (d, J = 7.0 Hz, 2 H), 6.61 
(d, J = 8.5 Hz, 1 H), 5.66 (d, J = 5.0 Hz, 1 H), 5.07 (app q, J = 
6.5 Hz, 2 H), 4.96 (br s, 1 H), 4.07 (q, J = 7.5 Hz, 1 H), 4.02–
3.93 (m, 2 H), 3.90–3.84 (m, 1 H), 3.76–3.65 (m, 3 H), 3.63 (s, 3 
H), 3.35 (br s, 1 H), 2.99–2.93 (m, 1 H), 2.90–2.84 (m, 2 H), 2.83 
(dd, J = 14.5, 7.0 Hz, 1 H, overlapping), 2.75 (dd, J = 12.5, 7.0 
Hz, 1 H), 2.27–2.18 (m, 1 H), 2.00–1.91 (m, 1 H), 1.86–1.59 (m, 10 
H) ppm; 13C NMR (125 MHz, CDCl3) δ 174.05, 156.34, 155.58, 138.29, 
137.85, 129.53, 129.34, 128.57, 126.64, 126.55, 109.45, 73.31, 
70.91, 69.74, 67.49, 55.07, 52.53, 51.16, 45.50, 41.84, 39.19, 
37.80, 36.60, 26.00, 24.11 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 




1,6-diphenylhexan-2-yl)carbamate (12c). The same procedure was 
used as described above for compound 12a. Compound 9 (0.50 g, 0.81 
mmol) was treated with ammonium formate (0.30 g, 4.83 mmol) and 
10% Pd/C (0.13 g) to give the corresponding deprotected amine 10, 
which was coupled with N-(methoxycarbonyl)-L-cyclopentylglycine 
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11c (0.19 g, 0.97 mmol) using DIEA (0.566 ml, 3.22 mmol) and HATU 
(0.48 g, 1.26 mmol) to provide the target compound 12c (0.32 g, 
64%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.29–7.22 (m, 4 
H), 7.21–7.16 (m, 4 H), 7.11 (d, J = 7.5 Hz, 2 H), 6.35 (d, J = 
6.5 Hz, 1 H), 5.67 (d, J = 5.0 Hz, 1 H), 5.12 (d, J = 7.5 Hz, 1 
H), 5.07 (q, J = 6.5 Hz, 1 H), 4.94 (d, J = 8.5 Hz, 1 H), 4.11 
(app q, J = 8.5 Hz, 1 H), 4.03–3.93 (m, 2 H), 3.92–3.83 (m, 2 H), 
3.77–3.66 (m, 3 H), 3.67 (s, 3 H, overlapping), 3.30 (br s, 1 H), 
2.99–2.93 (m, 1 H), 2.91–2.85 (m, 2 H), 2.82 (dd, J = 14.5, 6.5 
Hz, 1 H), 2.70 (dd, J = 13.5, 7.5 Hz, 1 H), 2.22–2.11 (m, 1 H), 
1.76–1.46 (m, 10 H), 1.27–1.14 (m, 2 H) ppm; 13C NMR (125 MHz, 
CDCl3) δ 172.09, 157.16, 155.62, 138.05, 137.55, 129.43, 129.36, 
128.66, 128.62, 126.80, 126.62, 109.46, 73.47, 70.93, 70.15, 
69.73, 59.47, 54.91, 52.63, 51.02, 45.53, 41.94, 41.81, 39.98, 
38.17, 29.59, 28.73, 26.00, 25.51, 25.28 ppm; HRMS (ESI) m/z: [M 
+ H]+ calcd for C34H46N3O8, 624.3280; found  624.3273; Anal. HPLC: 
tR 10.98 min, purity 96%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-((S)-2-((methoxycarbonyl)amino)propanamido)-1,6-
diphenylhexan-2-yl)carbamate (12d). The same procedure was used as 
described above for compound 12a. Compound 9 (0.45 g, 0.73 mmol) 
was treated with ammonium formate (0.28 g, 4.36 mmol) and 10% Pd/C 
(0.11 g) to give the corresponding deprotected amine 10, which was 
coupled with N-(methoxycarbonyl)-L-alanine 11d (0.14 g, 0.95 mmol) 
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using DIEA (0.377 ml, 2.18 mmol) and HATU (0.47 g, 1.23 mmol) to 
provide the target compound 12d (0.20 g, 47%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.28–7.22 (m, 4 H), 7.21–7.16 (m, 4 H), 7.11 
(d, J = 7.5 Hz, 2 H), 6.39 (d, J = 9.0 Hz, 1 H), 5.66 (d, J = 5.0 
Hz, 1 H), 5.17–5.09 (m, 1 H), 5.06 (q, J = 6.0 Hz, 1 H), 4.99 (d, 
J = 8.0 Hz, 1 H), 4.16–4.03 (m, 2 H), 3.99–3.91 (m, 2 H), 3.85 
(td, J = 8.0, 2.0 Hz, 1 H), 3.77–3.65 (m, 3 H), 3.67 (s, 3 H, 
overlapping), 2.97–2.91 (m, 1 H), 2.88 (d, J = 7.5 Hz, 2 H), 2.81 
(dd, J = 13.5, 5.5 Hz, 1 H), 2.71 (dd, J = 14.0, 8.0 Hz, 1 H), 
1.75–1.58 (m, 4 H), 1.25 (d, J = 7.0 Hz, 3 H) ppm; 13C NMR (125 
MHz, CDCl3) δ 172.73, 156.74, 155.66, 138.05, 137.61, 129.44, 
129.36, 128.65, 126.79, 126.66, 109.45, 73.48, 70.96, 70.03, 
69.73, 54.92, 52.61, 51.01, 45.54, 41.82, 39.87, 37.99, 26.00, 
18.76 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C30H40N3O8, 570.2810; 
found 570.2811.; Anal. HPLC: tR 9.14 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)-
1,6-diphenylhexan-2-yl)carbamate (12e). The same procedure was 
used as described above for compound 12a. Compound 9 (0.44 g, 0.70 
mmol) was treated with ammonium formate (0.27 g, 4.22 mmol) and 
10% Pd/C (0.11 g) to give the corresponding deprotected amine 10, 
which was coupled with N-(methoxycarbonyl)-L-valine  11e (0.15 g, 
0.84 mmol) using DIEA (0.364 ml, 2.11 mmol) and HATU (0.42 g, 1.10 
mmol) to provide the target compound 12e (0.29 g, 70%) as a white 
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solid. 1H NMR (500 MHz, CDCl3) δ 7.29–7.23 (m, 4 H), 7.22–7.17 (m, 
4 H), 7.10 (d, J = 7.5 Hz, 2 H), 6.30 (d, J = 9.0 Hz, 1 H), 5.67 
(d, J = 5.0 Hz, 1 H), 5.12–5.04 (m, 2 H), 4.93 (d, J = 8.5 Hz, 1 
H), 4.12 (q, J = 7.5 Hz, 1 H), 4.01–3.93 (m, 2 H), 3.92–3.83 (m, 
2 H), 3.75–3.67 (m, 3 H), 3.68 (s, 3 H, overlapping), 3.26 (br s, 
1 H), 2.99–2.93 (m, 1 H), 2.91–2.84 (m, 2 H), 2.81 (dd, J = 14.5, 
6.5 Hz, 1 H), 2.70 (dd, J = 13.5, 7.5 Hz, 1 H), 2.15–2.05 (m, 1 
H), 1.77–1.57 (m, 4 H), 0.90 (d, J = 7.0 Hz, 3 H), 0.78 (d, J = 
6.5 Hz, 3 H) ppm; 13C NMR (125 MHz, CDCl3) δ 171.58, 157.28, 155.67, 
138.00, 137.49, 129.42, 129.35, 128.67, 126.82, 126.66, 109.45, 
73.50, 70.93, 70.12, 69.72, 61.01, 54.88, 52.67, 51.09, 45.52, 
41.86, 40.04, 38.26, 30.50, 26.01, 19.54, 17.54 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C32H44N3O8, 598.3123; found 598.3122; Anal. 
HPLC: tR 10.23 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-5-((S)-
2-cyclopropyl-2-((methoxycarbonyl)amino)acetamido)-4-hydroxy-
1,6-diphenylhexan-2-yl)carbamate (12f).  The same procedure was 
used as described above for compound 12a. Compound 9 (0.46 g, 0.75 
mmol) was treated with ammonium formate (0.28 g, 4.49 mmol) and 
10% Pd/C (0.12 g) to give the corresponding deprotected amine 10, 
which was coupled with N-(methoxycarbonyl)-L-cyclopropylglycine 
11f (0.18 g, 1.05 mmol) using DIEA (0.390 ml, 2.25 mmol) and HATU 
(0.42 g, 1.05 mmol) to provide the target compound 12f (0.27 g, 
61%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.29–7.22 (m, 4 
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H), 7.21–7.15 (m, 4 H, overlapping), 7.10 (d, J = 7.5 Hz, 2 H), 
6.46 (d, J = 7.5 Hz, 1 H), 5.66 (d, J = 5.0 Hz, 1 H),  5.49 (d, J 
= 6.5 Hz, 1 H),  5.10–5.02 (m, 2 H), 4.10 (app, q, J = 8.0 Hz, 1 
H), 4.02–3.91 (m, 2 H), 3.89–3.82 (m, 1 H), 3.78–3.64 (m, 3 H), 
3.65 (s, 3 H, overlapping), 3.54–3.47 (br s, 1 H), 3.46–3.39 (m, 
1 H), 2.98–2.91 (m, 1 H), 2.89 (d, J = 7.5Hz, 2 H), 2.81 (dd, J = 
14.0, 6.0 Hz, 1 H), 2.70 (dd, J = 13.5, 7.5 Hz, 1 H), 1.75–1.57 
(m, 4 H), 0.96 (br s, 1 H), 0.55–0.44 (m, 2 H), 0.43–0.33 (m, 2 H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 171.65, 156.96, 155.58, 138.08, 
137.65, 129.44, 129.36, 128.62, 128.59, 126.72, 126.62, 109.43, 
73.41, 70.94, 69.70, 59.32, 54.96, 52.56, 50.82, 45.54, 41.63, 
39.78, 37.95, 25.98, 14.59, 3.68, 3.40 ppm; HRMS (ESI) m/z: [M + 
H]+ calcd for C32H42N3O8, 596.2967; found 596.2957; Anal. HPLC: tR 
10.54 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-((2S,3S)-2-((methoxycarbonyl)amino)-3-
methylpentanamido)-1,6-diphenylhexan-2-yl)carbamate (12g). The 
same procedure was used as described above for compound 12a. 
Compound 9 (0.44 g, 0.70 mmol) was treated with ammonium formate 
(0.27 g, 4.22 mmol) and 10% Pd/C (0.11 g) to give the corresponding 
deprotected amine 10, which was coupled with N-(methoxycarbonyl)-
L-isoleucine 11g (0.15 g, 0.84 mmol) using DIEA (0.364 ml, 2.11 
mmol) and HATU (0.42 g, 1.10 mmol) to provide the target compound 
12g (0.29 g, 40%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.29–
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7.23 (m, 4 H), 7.22–7.17 (m, 4 H), 7.11 (d, J = 7.5 Hz, 2 H), 6.26 
(d, J = 9.0 Hz, 1 H), 5.67 (d, J = 5.5 Hz, 1 H), 5.07 (q, J = 6.5 
Hz, 1 H), 5.02 (d, J = 8.0 Hz, 1 H), 4.89 (d, J = 8.0 Hz, 1 H), 
4.13 (q, J = 7.0 Hz, 1 H), 4.00–3.90 (m, 3 H), 3.89–3.84 (m, 1 H), 
3.75–3.67 (m, 3 H), 3.68 (s, 3 H, overlapping), 3.16 (br s, 1 H), 
2.99–2.93 (m, 1 H), 2.91–2.84 (m, 2 H), 2.81 (dd, J = 15.5, 7.5 
Hz, 1 H), 2.71 (dd, J = 14.0, 8.0 Hz, 1 H), 1.90–1.80 (m, 1 H),  
1.77–1.56 (m, 4 H), 1.33–1.22 (m, 1 H), 1.03–0.93 (m, 1 H), 0.87 
(d, J = 7.0 Hz, 3 H), 0.84 (t, J = 7.5 Hz, 3 H) ppm; 13C NMR (125 
MHz, CDCl3) δ 171.58, 157.21, 155.66, 137.99, 137.51, 129.42, 
129.36, 128.68, 128.64, 126.82, 126.64, 109.45, 73.49, 70.91, 
70.24, 69.73, 60.40, 56.02, 54.80, 52.67, 51.10, 45.52, 43.96, 
41.90, 40.06, 38.25, 36.82, 26.00, 24.48, 18.78, 17.40, 15.85, 
12.65, 11.57 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C33H46N3O8, 
612.3280; found 612.3275; Anal. HPLC: tR 10.82 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,4S,5S)-4-
hydroxy-5-((2S,3R)-2-((methoxycarbonyl)amino)-3-
methylpentanamido)-1,6-diphenylhexan-2-yl)carbamate (12h). The 
same procedure was used as described above for compound 12a. 
Compound 9 (0.53 g, 0.86 mmol) was treated with ammonium formate 
(0.33 g, 5.17 mmol) and 10% Pd/C (0.13 g) to give the corresponding 
deprotected amine 10, which was coupled with N-(methoxycarbonyl)-
L-alloisoleucine 11h (0.15 g, 0.84 mmol) using DIEA (0.450 ml, 
2.59 mmol) and HATU (0.59 g, 1.55 mmol) to provide the target 
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compound 12h (0.30 g, 58%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.29–7.23 (m, 4 H), 7.22–7.17 (m, 4 H), 7.11 (d, J = 7.0 
Hz, 2 H), 6.28 (d, J = 9.0 Hz, 1 H), 5.67 (d, J = 5.5 Hz, 1 H), 
5.07 (q, J = 6.5 Hz, 1 H), 4.96 (d, J = 7.5 Hz, 1 H), 4.93 (d, J 
= 8.0 Hz, 1 H), 4.16–4.09 (m, 1 H), 4.07 (dd, J = 7.0, 4.5 Hz, 1 
H), 3.97 (dd, J = 9.5, 6.5 Hz, 2 H), 3.90–3.84 (m, 1 H), 3.75–3.67 
(m, 3 H), 3.69 (s, 3 H, overlapping), 2.99–2.93 (m, 1 H), 2.90–
2.84 (m, 2 H), 2.81 (dd, J = 15.5, 7.5 Hz, 1 H), 2.72 (dd, J = 
14.0, 8.0 Hz, 1 H), 1.96–1.88 (m, 1 H),  1.76–1.57 (m, 4 H), 1.40–
1.30 (m, 1 H), 1.21–1.11 (m, 1 H), 0.90 (t, J = 7.0 Hz, 3 H), 0.67 
(d, J = 6.5 Hz, 3 H) ppm; 13C NMR (125 MHz, CDCl3) δ 171.84, 157.29, 
155.66, 138.02, 137.54, 129.42, 129.34, 128.67, 126.81, 126.67, 
109.45, 73.48, 70.89, 70.36, 69.73, 59.12, 54.88, 52.71, 51.16, 
45.52, 41.96, 39.95, 38.22, 36.82, 26.52, 26.00, 14.17, 11.80 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C33H46N3O8, 612.3280; found  
612.3277; Anal. HPLC: tR 10.87 min, purity 95%.
Methyl ((S)-1-(((2S,4S,5S)-5-(dibenzylamino)-4-hydroxy-1,6-
diphenylhexan-2-yl)amino)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
(13a). A solution of the Phe-Phe core intermediate 7 (1.00 g, 2.16 
mmol) in DMF (15 mL) was cooled to 0 °C and treated with N-
(methoxycarbonyl)-L-tert-leucine 11a (0.48 g, 2.58 mmol), DIEA 
(1.1 ml, 6.30 mmol) and HATU (1.28 g, 3.36 mmol). The resulting 
reaction mixture was stirred at room temperature for 4 h, 
concentrated under reduced pressure, and dried under high vacuum. 
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The residue was purified by flash column chromatography (RediSep 
Gold, 24 g, gradient elution with 0–10% methanol/dichloromethane) 
to give the intermediate 13a (1.20 g, 87%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.34–7.29 (m, 4 H), 7.28–7.23 (m, 4 H), 
7.22–7.14 (m, 8 H), 7.06 (d, J = 7.5 Hz, 2 H), 7.00 (d, J = 6.5 
Hz, 2 H), 6.55 (d, J = 6.0 Hz, 1 H), 5.42 (d, J = 9.0 Hz, 1 H), 
4.65 (br s, 1 H), 4.06–3.97 (m, 1 H), 3.91–3.79 (m, 3 H), 3.66 (s, 
3 H), 3.53 (t, J = 8.5 Hz, 1 H), 3.36 (d, J = 13.5 Hz, 2 H), 3.06 
(dd, J = 14.5, 5.5 Hz, 1 H), 2.92 (dd, J = 13.5, 5.0 Hz, 1 H), 
2.76 (q, J = 7.0 Hz, 1 H), 2.59–2.46 (m, 2 H), 1.50 (dd, J = 14.5, 
5.0 Hz, 1 H), 1.17–1.08 (m, 1 H), 0.99 (s, 9 H) ppm; 13C NMR (125 
MHz, CDCl3) δ 170.57, 157.02, 140.03, 138.77, 138.10, 129.54, 
129.15, 129.06, 128.80, 128.64, 128.36, 127.49, 126.40, 126.29, 
69.83, 64.22, 63.31, 53.90, 52.34, 51.54, 41.12, 37.42, 34.78, 
32.01, 26.60 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C40H50N3O4, 
636.3796; found 636.3793.
Methyl (1-(((2S,4S,5S)-5-(dibenzylamino)-4-hydroxy-1,6-
diphenylhexan-2-yl)carbamoyl)cyclopentyl)carbamate (13b). The 
same procedure was used as described above for 13a. The Phe-Phe 
core intermediate 7 (1.00 g, 2.16 mmol) was coupled with N-
(methoxycarbonyl)-cycloleucine 11b (0.47 g, 2.50 mmol) using DIEA 
(1.1 ml, 6.30 mmol) and HATU (1.21 g, 3.18 mmol) to provide 13b 
(1.30 g, 95%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.33–
7.27 (m, 4 H), 7.26–7.15 (m, 12 H), 7.11 (d, J = 7.5 Hz, 2 H), 
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7.04 (d, J = 7.0 Hz, 2 H), 6.80 (br s, 1 H), 5.00 (br s, 1 H), 
4.32 (br s, 1 H), 4.04 (m, 1 H), 3.93 (d, J = 13.0 Hz, 2 H), 3.55 
(s, 4 H), 3.39 (d, J = 13.0 Hz, 2 H), 3.05 (dd, J = 13.5, 5.0 Hz, 
1 H), 2.81 (dd, J = 13.5, 5.0 Hz 1 H), 2.74 (app q, J = 7.5 Hz, 1 
H), 2.70–2.59 (m, 2 H), 2.28–2.17 (m, 1 H), 2.12–2.04 (m, 1 H), 
1.93–1.78 (m, 1 H), 1.77–1.65 (m, 4 H), 1.51 (dd, J = 14.5, 3.5 
Hz, 1 H), 1.35–1.24 (m, 1 H) ppm; 13C NMR (125 MHz, CDCl3) δ 173.64, 
156.09, 140.40, 139.32, 138.38, 129.69, 129.27, 129.10, 128.74, 
128.57, 128.30, 127.33, 126.28, 70.03, 67.31, 64.31, 54.27, 52.20, 
50.93, 41.33, 38.17, 37.23, 36.65, 31.65, 24.30, 24.26 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C40H48N3O4, 634.3640; found 634.3615.
Methyl ((S)-1-cyclopentyl-2-(((2S,4S,5S)-5-(dibenzylamino)-4-
hydroxy-1,6-diphenylhexan-2-yl)amino)-2-oxoethyl)carbamate (13c). 
The same procedure was used as described above for 13a. The Phe-
Phe core intermediate 7 (1.04 g, 2.23 mmol) was coupled with N-
(methoxycarbonyl)-cyclopentylglycine 11c (0.45 g, 2.23 mmol) using 
DIEA (1.17 ml, 6.69 mmol) and HATU (1.02 g, 2.68 mmol) to give 13c 
(1.30 g, 90%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.34–
7.28 (m, 4 H), 7.27–7.22 (m, 4 H), 7.21–7.14 (m, 8 H), 7.06 (d, J 
= 7.0 Hz, 2 H), 7.00 (d, J = 6.5 Hz, 2 H), 6.57 (d, J = 5.5 Hz, 1 
H), 5.22 (d, J = 8.0 Hz, 1 H), 4.66 (br s, 1 H), 4.06–3.98 (m, 1 
H), 3.97–3.90 (m, 1 H), 3.86 (d, J = 13.0 Hz, 2 H), 3.64 (s, 3 H), 
3.53 (t, J = 8.5 Hz, 1 H), 3.36 (d, J = 13.0 Hz, 2 H), 3.05 (dd, 
J = 14.5, 5.5 Hz, 1 H), 2.88 (dd, J = 13.5, 5.0 Hz, 1 H), 2.76 (q, 
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J = 6.5 Hz, 1 H), 2.59–2.47 (m, 2 H), 2.23 (app q, J = 8.0 Hz, 1 
H), 1.74–1.54 (m, 4 H), 1.53–1.43 (m, 3 H), 1.40–1.22 (m, 2 H), 
1.15–1.06 (m, 1 H) ppm; 13C NMR (125 MHz, CDCl3) δ  171.64, 157.03, 
140.10, 138.79, 138.14, 129.56, 129.16, 129.11, 128.83, 128.66, 
128.38, 127.51, 126.42, 126.33, 70.00, 64.20, 58.96, 53.88, 52.38, 
51.53, 42.75, 41.40, 37.59, 32.05, 29.29, 28.55, 25.46, 25.20 ppm; 




dimethylbutanamido)-1,6-diphenylhexan-2-yl)carbamate (15a). A 
solution of intermediate 13a (1.20 g, 1.89 mmol) in anhydrous MeOH 
(15 mL) was treated with ammonium formate (0.71 g, 11.32 mmol) and 
10% Pd/C (0.3 g). The resulting reaction mixture was stirred at 50 
°C for 15 h, cooled to room temperature, filtered through a pad of 
Celite, and the filtrate was concentrated under reduced pressure. 
The resulting deprotected amine was dissolved in acetonitrile (10 
mL) and the solution was cooled to 0 °C. DIEA (0.98 ml, 5.66 mmol) 
was added followed by bis-THF activated carbonate 8 (0.56 g, 2.08 
mmol). The reaction mixture was warmed up to room temperature and 
stirred for 24 h. The solvents were removed under reduced pressure, 
and the residue was purified by automated flash chromatography 
using a silica gel column (RediSep Gold, 40 g, gradient elution 
with 0–15% methanol/dichloromethane) to provide the target 
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compound 15a (0.36 g, 31%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.29–7.22 (m, 4 H), 7.21–7.16 (m, 4 H), 7.10 (d, J = 7.0 
Hz, 2 H), 6.07 (d, J = 6.0 Hz, 1 H), 5.67 (d, J = 5.0 Hz, 1 H), 
5.36–5.22 (m, 1 H), 5.10 (d, J = 9.5 Hz, 1 H), 5.05 (q, J = 6.5 
Hz, 1 H), 4.22–4.13 (m, 1 H), 3.98 (dd, J = 9.5, 6.5 Hz, 1 H), 
3.87 (td, J = 8.5, 3.0 Hz, 1 H), 3.82–3.58 (m, 6 H), 3.67 (s, 3 H, 
overlapping), 2.98–2.90 (m, 1 H), 2.88–2.73 (m, 4 H), 1.73–1.57 
(m, 4 H), 0.91 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 171.09, 
157.19, 155.83, 138.13, 137.12, 129.41, 129.32, 128.73, 128.64, 
126.91, 126.61, 109.47, 73.39, 70.98, 70.35, 69.78, 63.35, 56.60, 
52.65, 49.38, 45.49, 41.43, 40.37, 38.87, 34.35, 26.65, 25.98 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C33H46N3O8, 612.3280; found 
612.3278; Anal. HPLC: tR 10.70 min, purity 97%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3S,5S)-3-
hydroxy-5-(1-((methoxycarbonyl)amino)cyclopentane-1-
carboxamido)-1,6-diphenylhexan-2-yl)carbamate (15b). The same 
procedure was used as described above for 15a. Compound 13b (0.70 
g, 1.10 mmol) was treated with ammonium formate (0.42 g, 6.63 mmol) 
and 10% Pd/C (0.17 g) to give the corresponding deprotected amine, 
which was subsequently treated with DIEA (0.380 ml, 2.20 mmol) and 
bis-THF activated carbonate 8 (0.33 g, 1.21 mmol) to provide the 
target compound 15b (0.23 g, 35%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 7.29–7.22 (m, 4 H), 7.21–7.16 (m, 4 H), 7.11 (d, J = 
7.0 Hz, 2 H), 6.49 (d, J = 7.0 Hz, 1 H), 5.67 (d, J = 5.5 Hz, 1 
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H), 5.14 (d, J = 9.5 Hz, 1 H), 5.07 (q, J = 6.5 Hz, 1 H), 4.97 (s, 
1 H), 4.23 (br s, 1 H), 3.99 (dd, J = 9.5, 6.5 Hz, 1 H ), 3.94 (br 
s, 1 H), 3.88 (td, J = 8.0, 2.0 Hz, 1 H ), 3.85–3.69 (m, 4 H), 
3.65 (s, 3 H), 2.98–2.91 (m, 1 H), 2.89 (dd, J = 14.0, 7.5 Hz, 1 
H, overlapping ), 2.83 (dd, J = 15.5, 8.0 Hz, 2 H ), 2.71 (dd, J 
= 13.5, 7.5 Hz, 1 H ), 2.19–2.11 (m, 1 H), 1.94–1.59 (m, 11 H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 173.71, 156.67, 155.77, 138.34, 
137.62, 129.52, 129.40, 128.56, 126.73, 126.49, 109.51, 73.29, 
71.11, 70.40, 69.81, 67.39, 57.24, 52.62, 49.96, 45.50, 41.98, 
40.64, 39.01, 37.14, 36.65, 26.03, 24.01, 23.81 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C33H44N3O8, 610.3123; found 610.3118; Anal. 
HPLC: tR 7.73 min, purity 95%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3S,5S)-5-((S)-
2-cyclopentyl-2-((methoxycarbonyl)amino)acetamido)-3-hydroxy-
1,6-diphenylhexan-2-yl)carbamate (15c). The same procedure was 
used as described above for 15a. Compound 13c (0.70 g, 1.08 mmol) 
was treated with ammonium formate (0.41 g, 6.48 mmol) and 10% Pd/C 
(0.17 g) to give the corresponding deprotected amine, which was 
subsequently treated with DIEA (0.570 ml, 3.24 mmol) and bis-THF 
activated carbonate 8 (0.32 g, 1.19 mmol) to provide the target 
compound 15c (0.26 g, 39%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.29–7.22 (m, 4 H), 7.21–7.16 (m, 4 H), 7.11 (d, J = 7.5 
Hz, 2 H), 6.29 (br s, 1 H), 5.67 (d, J = 5.0 Hz, 1 H), 5.19–5.07 
(m, 2 H), 5.05 (q, J = 6.0 Hz, 1 H, overlapping), 4.24–4.15 (m, 1 
Page 59 of 83
ACS Paragon Plus Environment






























































H), 3.98 (dd, J = 9.5, 6.0 Hz, 1 H), 3.87 (td, J = 8.0, 2.0 Hz, 1 
H), 3.85–3.78 (m, 2 H, overlapping), 3.77–3.63 (m, 3 H), 3.67 (s, 
3 H, overlapping), 2.99–2.91 (m, 1 H), 2.90–2.71 (m, 4 H), 2.22–
2.09 (m, 1 H), 1.83–1.45 (m, 10 H), 1.22–1.07 (m, 2 H) ppm; 13C NMR 
(125 MHz, CDCl3) δ 172.11, 157.29, 155.83, 138.24, 137.34, 129.45, 
129.34, 128.63, 128.60, 126.80, 126.56, 109.48, 73.36, 71.00, 
70.33, 69.79, 59.46, 56.68, 52.71, 49.33, 45.54, 41.70, 41.46, 
40.51, 38.92, 29.48, 28.71, 25.97, 25.47, 25.22 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C34H46N3O8, 624.3279; found 624.3282; Anal. 
HPLC: tR 10.83 min, purity 99%.
Protease Gene Construction.
Protease gene construction was carried out as previously 
described.36, 37 The NL4-3 strain has four naturally occurring 
polymorphisms in the protease relative to the SF2 strain.  In 
short, the protease variant genes (I84V, I50V/A71V) were 
constructed using QuikChange site-directed mutagenesis (Genewiz) 
onto NL4-3 wild-type protease on a pET11a plasmid with codon 
optimization for protein expression in Escherichia coli. A Q7K 
mutation was included to prevent autoproteolysis.38 
Protein Expression and Purification. The expression, isolation, 
and purification of WT and mutant HIV-1 proteases used for the 
kinetic assays and crystallization were carried out as previously 
described.36, 37 Briefly, the gene encoding the HIV protease was 
subcloned into the heat-inducible pXC35 expression vector (ATCC) 
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and transformed into E. coli TAP-106 cells. Cells grown in 6 L of 
Terrific Broth were lysed with a cell disruptor and the protein 
was purified from inclusion bodies.39 The inclusion body 
centrifugation pellet was dissolved in 50% acetic acid followed by 
another round of centrifugation to remove impurities. Size 
exclusion chromatography was used to separate high molecular 
weight proteins from the desired protease. This was carried out on 
a 2.1 L Sephadex G-75 superfine column (Millipore Sigma) 
equilibrated with 50% acetic acid. The cleanest fractions of HIV 
protease were refolded into a 10-fold dilution of 0.05 M sodium 
acetate at pH 5.5, 5% ethylene glycol, 10% glycerol, and 5 mM DTT. 
Folded protein was concentrated down to 1–2 mg/mL and stored. This 
stored protease was used in Ki assays. For crystallography, a final 
purification was performed with a Pharmacia Superdex 75 FPLC column 
equilibrated with 0.05 M sodium acetate at pH 5.5, 5% ethylene 
glycol, 10% glycerol, and 5 mM DTT. Protease fractions purified 
from the size exclusion column were concentrated to 1–2 mg/mL using 
an Amicon Ultra-15 10-kDa device (Millipore) for crystallization.
Enzyme Inhibition Assays. The enzyme inhibition assays were 
carried out as previously described.33, 40 To determine the enzyme 
inhibition constant (Ki), in a 96-well plate, each inhibitor was 
serially diluted, including a no drug control, and incubated with 
0.35 nM protein for 1 hour. A 10-amino acid substrate containing 
an optimized protease cleavage site with an EDANS/DABCYL FRET pair 
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was dissolved in 4% DMSO at 120 µM. Using the Envision plate 
reader, 5 µL of the 120 µM substrate was added to the 96-well plate 
to a final concentration of 10 µM. The fluorescence was observed 
with an excitation at 340 nm and emission at 492 nm and monitored 
for 200 counts, for approximately 60 min. Data was analyzed with 
Prism7. DRV was used as a control in all assays.
Antiviral Assays. 293T and TZM-BL41 cells (NIH AIDS Research and 
Reference Reagent Program) were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum in the 
presence of penicillin and streptomycin at 37 °C with 5% CO2. To 
determine the concentration of drugs achieving 50% inhibition of 
infection compared with the drug-free control, 4.5×106 293T cells 
were seeded onto a 10-cm plate 24 h before transfection. Cells 
were transfected with 8 µg of either the wild-type plasmid, 
infectious molecular clone pNL-CH derived from the pNL4-3 clone of 
HIV-1 using FuGENE 6 transfection reagent (Roche). The culture 
supernatant of 293T cells transfected with wild-type or PI-
resistant HIV-1 variant was removed 18 h after transfection and 
the cells were washed with 1 × PBS. The 293T cells were collected 
and transferred to wells of a 24-well plate. Briefly, each drug 
was serially diluted in the culture medium and the dilutions were 
added to the wells of a 24-well plate. The 293T cells (0.5 × 106 
per well) collected from the transfection were added to wells 
containing various concentrations of drug. The culture supernatant 
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containing virus particles was harvested 18 h after the 293T cells 
were reseeded in the presence of drug. This supernatant was 
filtered through a 0.45-µm-pore-size membrane (Millipore) to 
remove cell debris then used to infect 2 × 104 TZM-BL cells in a 
96-well plate following a procedure previously described.42 The 
culture supernatant was removed from each well 48 h post-infection, 
and the cells were washed with 1 × PBS. For the luciferase assay, 
infected TZM-BL cells were lysed in 1× reporter lysis buffer 
(Promega) and the cells were kept at 80 °C. After one freeze-thaw 
cycle, the cell lysates were transferred into a 96-well assay plate 
(Costar), and luciferase activity was measured using a luminometer 
(Promega). The culture supernatant harvested from 293T cells 
reseeded in the absence of drugs was used as a drug-free control. 
EC50 was determined based on a dose-response curve generated using 
GraphPad Prism (version 7.0).
Protein Crystallization. The condition reliably producing 
cocrystals of NL4-3 WT protease bound to PIs was discovered and 
optimized as previously described.40, 43 Briefly, all cocrystals 
were grown at room temperature by hanging drop vapor diffusion 
method in a 24-well VDX hanging-drop trays (Hampton Research) with 
a protease concentration of 1.4–1.7 mg/mL with 3-fold molar excess 
of inhibitors and mixed with the precipitant solution at a 1:2 
ratio. The reservoir solution was 23–27% (w/v) ammonium sulfate 
with 0.1 M bis-Tris-methane buffer at pH 5.5, and the 
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crystallization drops were set with 2 µL of well solution and 1 µL 
of protein-inhibitor solution and micro-seeded with a cat whisker. 
Diffraction quality crystals were obtained within 1 week. As data 
were collected at 100 K, cryogenic conditions contained the 
precipitant solution supplemented with 25% glycerol. 
X-Ray Data Collection and Structure Solution. X-ray diffraction 
data were collected and solved as previously described.36, 40, 43 
Diffraction quality crystals were flash frozen under a cryostream 
when mounting the crystals either at our in-house Rigaku_Saturn944 
X-ray system or the Chicago APS Synchrotron Beamline 23-1D-D. The 
cocrystal diffraction intensities from the Rigaku system were 
indexed, integrated, and scaled using HKL3000.44 Structures were 
solved using molecular replacement with PHASER.45 Model building 
and refinement were performed using Coot46 and Phenix.47 Ligands 
were designed in Maestro and the output sdf files were used in the 
Phenix program eLBOW48 to generate cif files containing atomic 
positions and  constraints necessary for ligand refinement. 
Iterative rounds of crystallographic refinement were carried out 
until convergence was achieved. To limit bias throughout the 
refinement process, five percent of the data were reserved for the 
free R-value calculation.49 MolProbity50 was applied to evaluate 
the final structures before deposition in the PDB. Structure 
analysis, superposition and figure generation was done using 
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PyMOL.51 X-ray data collection and crystallographic refinement 
statistics are presented in the Supporting Information (Table S1).
The cocrystal structures of all new hybrid compounds were solved 
in the P212121 space group with one protease homodimer in the 
asymmetric unit and only one orientation of the bound inhibitor in 
the active site, which was crucial for direct comparison of 
inhibitor structures. The cocrystal structure of compound 4 was 
solved in the P21 space group with two protease homodimers in the 
asymmetric unit, and one inhibitor bound to each dimer in one 
orientation, allowing one P21 dimer to be directly compared to the 
crystal structures solved in the P212121 space group. Three 
structures (10a, 10b, 13c) had significant electron density at the 
flap tips (residues 50–51) indicating that the backbone atoms 
interacted in two conformations, as both hydrogen bond donors and 
acceptors. Figure generation and structural analysis calculations 
(distance differences, vdW, hydrogen bonds) were performed with 
the flap tips modeled in one conformation while the other 
conformation was excluded. Compound 5 formed cocrystals but were 
inadequate for X-ray data collection.
Intermolecular vdW Contact Analysis of Crystal Structures. To 
calculate the intermolecular vdW interaction energies the crystal 
structures were prepared using the Schrödinger Protein Preparation 
Wizard.52 Hydrogen atoms were added, protonation states were 
determined, and the structures were minimized. The protease active 
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site was monoprotonated at Asp25. Subsequently, force field 
parameters were assigned using the OPLS3 force field.53 Interaction 
energies between the inhibitor and protease were estimated using 
a simplified Lennard-Jones potential, as previously described in 
detail.54 Briefly, the vdW energy was calculated for pairwise 
interactions depending on the types of atoms interacting and the 
distance between them. For each protease residue, the change in 
vdW interactions relative to a reference complex in the same space 
group was also calculated for each variant structure.
Molecular Dynamics Simulations
System Preparation. High resolution crystal structures of LPV and 
the designed inhibitors bound to WT protease were prepared using 
the Protein Preparation Wizard using Maestro within the 
Schrödinger Suite52 as previously described.55, 56 Briefly, missing 
atoms were added using Prime57 and PROPKA58 was used to determine 
the protonation state of the side chains at pH 7.0. The catalytic 
aspartic acid with a pKa higher than 7.0 was protonated whereas 
the one with a pKa less than 7.0 was unprotonated. Co-crystallized 
fragments such as phosphate ions were removed. Lastly, the 
structure was minimized to a convergence criterion of 0.3 Å using 
Impref.59
Molecular Dynamics Simulations. The prepared systems were placed 
in a cubic TIP3P implicit water box measuring 12Å on each side. 
Molecular dynamics simulations were carried out as previously 
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described55 using Desmond within Schrödinger Suite.52 Briefly, 
chloride ions were used to neutralize the system and 0.15 M salt 
were added using sodium and chloride ions. The OPLS3 force field 
was used to parameterize the ligand and protein. Prior to starting 
the 100 ns MD simulations, the solvated system was minimized using 
the stepwise procedure described previously.55 Triplicates of 100 
ns simulations for LPV and the designed inhibitors in complex with 
WT protease each with a randomized velocity were started using a 
protocol previously developed.55, 56 The root-mean-square deviation 
(RMSD) and root-mean-square fluctuation (RMSF) were calculated 
using tools within the Schrodinger Suite.
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12f, 12g, 12h, 15a, 15b, and 15c are 6DGX, 6PJB, 6PJC, 6PJD, 6PJE, 
6PJG, 6PJH, 6PJI, 6PJK, 6PJL, 6PJM, 6PJN, and 6PJO, respectively. 




*Akbar Ali: Phone: +1 508 856 8873; Fax: +1 508 856 6464; E-mail: 
Akbar.Ali@umassmed.edu




Celia A. Schiffer: 0000-0003-2270-6613
Author Contributions
§These authors contributed equally to this work.
Present Addresses
For LNR: Raybow Pharmaceutical USA, 158 McLean Road, Brevard, 
North Carolina 28712, United States
Notes
The authors declare no competing financial interest.
Page 68 of 83
ACS Paragon Plus Environment































































This work was supported by a grant from the National Institute 
of General Medical Sciences of the NIH (P01 GM109767).
ACKNOWLEDGMENT
This research used resources of the Advanced Photon Source, a 
U.S. Department of Energy (DOE) Office of Science User Facility 
operated for the DOE Office of Science by Argonne National 
Laboratory under Contract No. DE-AC02-06CH11357. GM/CA@APS has 
been funded in whole or in part with Federal funds from the 
National Cancer Institute (ACB-12002) and the National Institute 
of General Medical Sciences (AGM-12006). The Eiger 16M detector 
was funded by an NIH–Office of Research Infrastructure Programs, 
High-End Instrumentation Grant (1S10OD012289-01A1). We thank the 
beamline specialists at 23-ID-D for their help in data collection. 
We thank Ellen A. Nalivaika for providing the HIV-1 protease 
variants, the AIDS Research and Reference Reagent Program (NIAD, 
NIH) for reference protease inhibitors, and Drs. William Royer, 
Brian Kelch and members of the Schiffer and Miller laboratories 
for helpful discussions. This work was supported by a grant from 
the National Institute of General Medical Sciences of the NIH (P01 
GM109767).
ABBREVIATIONS
Page 69 of 83
ACS Paragon Plus Environment






























































ATV, atazanavir; HIV-1, human immunodeficiency virus type 1; bis-THF, bis-tetrahydrofuran; 
Boc, tert-butoxycarbonyl; DIEA, N,N-diisopropylethylamine; DRV, darunavir; HATU, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate;
FRET, fluorescence resonance energy transfer; LPV, lopinavir; MDR, multidrug-resistant; PIs, 
protease inhibitors; SAR, structure-activity relationships; TFA, trifluoroacetic acid; THF, 
tetrahydrofuran.
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